A review of fragile X premutation disorders: expanding the psychiatric perspective.
BACKGROUND
Fragile X premutation conditions are associated with a significant degree of psychopathology and thus are of interest to the psychiatrist. Remarkable advances at the molecular level have enhanced our understanding of fragile X premutation disorders.


OBJECTIVE
The authors review the genetic, molecular, neuroimaging, and clinical (systemic, neurologic, and psychiatric) manifestations of the premutation carrier state (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene.


METHODS
The search for the psychiatric clinical manifestations of fragile X-associated conditions was accomplished by PubMed for clinical papers published between 1970 and 2008 with the following search terms: Fragile X syndrome, depression, psychosis, anxiety, and dementia.


METHODS
Articles addressing psychiatric symptoms in premutation carriers based on review of the abstracts were reviewed. As the majority of the literature on this topic is based on case reports and small case series, these were included in the database.


RESULTS
Reported clinical manifestations of psychiatric illness in premutation carriers include an apparently significant rate of cognitive, mood, anxiety, and other psychiatric disorders. Fragile X premutation-associated conditions are part of the clinical differential diagnosis of several psychiatric syndromes, particularly in pedigrees with known fragile X syndrome cases.


CONCLUSIONS
Fragile X-associated psychiatric manifestations serve as a useful model for a molecular genesis of neuropsychiatric illness. Because of the multigenerational expression of fragile X-associated neuropsychiatric illness, there is a prominent role for genetic testing and genetic counseling of patients and their relatives. Genetic testing is confirmatory of the FMR1 premutation and is an essential component of the clinical evaluation. Psychopharmacologic and psychotherapeutic treatment of fragile X-associated psychiatric illnesses may improve patient function and assist in adaptation to the burden of a genetic neuropsychiatric illness.
Bourgeois
James A
JA
Department of Psychiatry and Behavioral Sciences, University of California Davis Medical Center, Sacramento, CA 95817, USA. james.bourgeois@ucdmc.ucdavis.edu
Coffey
Sarah M
SM
Rivera
Susan M
SM
Hessl
David
D
Gane
Louise W
LW
Tassone
Flora
F
Greco
Claudia
C
Finucane
Brenda
B
Nelson
Lawrence
L
Berry-Kravis
Elizabeth
E
Grigsby
Jim
J
Hagerman
Paul J
PJ
Hagerman
Randi J
RJ
D000328:Adult; D001008:Anxiety Disorders / Q000175:diagnosis / Q000235:genetics / Q000523:psychology; D001259:Ataxia / Q000235:genetics; D001284:Atrophy; D001921:Brain / Q000473:pathology; D002648:Child; D015897:Comorbidity; D003704:Dementia / Q000175:diagnosis / Q000235:genetics / Q000523:psychology; D003937:Diagnosis, Differential; D005260:Female; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics*; D005600:Fragile X Syndrome / Q000175:diagnosis / Q000235:genetics* / Q000523:psychology; D006580:Genetic Carrier Screening; D005817:Genetic Counseling; D005820:Genetic Testing; D006801:Humans; D008607:Intellectual Disability / Q000175:diagnosis / Q000235:genetics / Q000523:psychology; D008279:Magnetic Resonance Imaging; D008297:Male; D001523:Mental Disorders / Q000175:diagnosis / Q000235:genetics* / Q000523:psychology; D019964:Mood Disorders / Q000175:diagnosis / Q000235:genetics / Q000523:psychology; D010641:Phenotype; D016649:Primary Ovarian Insufficiency / Q000235:genetics; D014202:Tremor / Q000235:genetics; D018911:Trinucleotide Repeats
D051860:Fragile X Messenger Ribonucleoprotein 1; C497683:FMR1 protein, human